Fortress Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fortress Biotech, Inc. on January 13, 2026. The filing reports a significant regulatory milestone regarding the Company's product pipeline and a related asset transfer to a subsidiary.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than periodic financial results.
Material Changes and Events
- FDA Approval: The U.S. Food and Drug Administration (FDA) approved ZYCUBO® (copper histidinate, formerly CUTX-101) for the treatment of Menkes disease in pediatric patients.
- Priority Review Voucher (PRV): A Rare Pediatric Disease PRV was issued in connection with the approval.
- Asset Transfer: The PRV will be transferred to Cyprium Therapeutics, Inc., a majority-owned subsidiary of Fortress Biotech.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the FDA approval and the PRV issuance. The filing does not contain forward-looking guidance, risk factors, or discussion of contingencies beyond the event described in Item 8.01. The full press release is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for ZYCUBO®.
- Confirm the valuation and potential sale terms of the Rare Pediatric Disease PRV held by Cyprium Therapeutics.
- Review the full text of the press release (Exhibit 99.1) for details on the Menkes disease treatment indication.
- Assess the impact of the PRV transfer on the consolidated financial statements of Fortress Biotech.